PeptideLabs Logo
PeptideLabs
Documentación de Calidad
Back to all 64 profiles
Clinical researchEn investigación clínicaWADA

Community protocol · ARA-290 / Cibinetide

ARA-290 / Cibinetide: community information and evidence, clearly separated.

A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.

Also known as: ARA 290 · Cibinetide · pHBSP

Sources checked: 27 August 2026

Aviso importante de seguridad y responsabilidad

Esta página documenta y evalúa información de comunidades. No es consejo médico ni terapéutico, asesoramiento individual ni invitación al uso.

No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.

Quick context

ARA-290 / Cibinetide

Se ha estudiado para resultados inflamatorios, nerviosos y metabólicos; carece de aprobación medicinal general.

Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.

Amounts, timing and cycles

Clinical research

Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.

Amount status

Trials use protocol-bound amounts and escalation; this does not create a safe community dose.

Profile evidence level: clinical.

Timing

Timing is set by each trial protocol and may differ substantially between studies.

No individual recommendation.

Cycle/duration

Duration is study-specific and ends according to protocol; long-term safety may remain unknown.

No individual recommendation.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Reconstitución y conversión U-100

Calculadora de reconstitución

For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.

Calculadora de reconstitución

Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.

Concentration

3,333.33 µg/ml

Calculated volume

0.06 ml

U-100 units

6 U

Calculated portions per vial

50

Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.

Mechanism and research questions

Non-haematopoietic erythropoietin-derived tissue-protective peptide

ARA-290 / Cibinetide is classified as “Non-haematopoietic erythropoietin-derived tissue-protective peptide”. Se ha estudiado para resultados inflamatorios, nerviosos y metabólicos; carece de aprobación medicinal general. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Protección tisular derivada de EPO

Esto estudia si un fragmento derivado de la eritropoyetina puede aportar protección tisular sin la actividad formadora de sangre de la hormona original, de forma similar a una pieza que conserva solo una de varias funciones. Se miden la supervivencia celular y los marcadores de inflamación en modelos de laboratorio.

02

Señalización neuroprotectora

Se examina si una sustancia puede proteger las células nerviosas del estrés o el daño, por ejemplo tras la falta de oxígeno en un modelo celular. Se miden la supervivencia celular y los marcadores de señalización en tejido nervioso en condiciones de laboratorio.

03

Péptido inmunomodulador

Esto estudia cómo un péptido ajusta la actividad de las células inmunitarias, de forma similar a un regulador que refuerza o atenúa la respuesta inmunitaria. Se miden los recuentos de células inmunitarias y los marcadores de inflamación en los estudios.

What communities discuss

These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Foros de recuperación y lesiones

Se comparan los tiempos de recuperación personales tras lesiones deportivas usando diferentes péptidos reparadores, a menudo basándose en escalas subjetivas de dolor. Estas evoluciones individuales están influenciadas por muchos otros factores y no prueban eficacia.

Foros de biohacking y longevidad

Los usuarios comparan combinaciones de péptidos ensambladas por ellos mismos con el objetivo de influir en los procesos de envejecimiento o los niveles de energía, a menudo basándose en análisis de sangre o escalas subjetivas de bienestar. Los autoexperimentos personales y las promesas de marketing no reemplazan a los estudios controlados a largo plazo en humanos.

Discusión de origen y pureza

Se discute qué proveedores se consideran más confiables y cómo difieren los resultados de las pruebas de pureza entre lotes. Estas evaluaciones comunitarias se basan en muestras limitadas y no reemplazan las pruebas de laboratorio independientes de cada lote individual.

Adverse effects and risk boundaries

  • Muchos llamados péptidos reparadores carecen de estudios humanos controlados. Persisten riesgos de efectos sistémicos desconocidos, reacciones inmunes, efectos vasculares o hemorrágicos e infección/contaminación por inyección.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Exclusion groups and professional assessment

  • Embarazo, cáncer, infección activa, trastornos de coagulación, cirugía prevista y enfermedades inmunes relevantes exigen valoración especialmente estricta o evitar el uso.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • No existe un esquema validado de seguimiento para péptidos reparadores no aprobados. Según el caso pueden ser relevantes exploración, inflamación, hemograma, hígado/riñón y coagulación.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

En ensayos clínicos

Falta una aprobación médica general a pesar del estudio clínico.

Published evidence

La sustancia se está estudiando actualmente en ensayos clínicos estructurados en humanos, pero aún no existe una aprobación general.

ARA-290 se deriva de la eritropoyetina, pero actúa sin su efecto formador de sangre, a diferencia de los productos EPO clásicos.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and error sources

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

En investigación clínica

Candidato en desarrollo clínico; no es un medicamento aprobado.

WADA 2026

This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile